CN100441580C - Quinolyl dione derivative and its application in preparing antibiotic medicine - Google Patents

Quinolyl dione derivative and its application in preparing antibiotic medicine Download PDF

Info

Publication number
CN100441580C
CN100441580C CNB2006100364840A CN200610036484A CN100441580C CN 100441580 C CN100441580 C CN 100441580C CN B2006100364840 A CNB2006100364840 A CN B2006100364840A CN 200610036484 A CN200610036484 A CN 200610036484A CN 100441580 C CN100441580 C CN 100441580C
Authority
CN
China
Prior art keywords
dione derivative
quinolyl dione
medicine
quinolyl
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006100364840A
Other languages
Chinese (zh)
Other versions
CN1887884A (en
Inventor
古练权
黄志纾
刘忠
张竹林
鲍雅丹
安林坤
黄世亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Priority to CNB2006100364840A priority Critical patent/CN100441580C/en
Publication of CN1887884A publication Critical patent/CN1887884A/en
Application granted granted Critical
Publication of CN100441580C publication Critical patent/CN100441580C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to one kind of quinolyl dione derivative and its application in preparing antibiotic medicine, especially medicine for resisting meticillin resistant Staphylococcus aureus (MRSA). Experiment shows that the quinolyl dione derivative has powerful inhibition on Gram-positive bacteria, especially MRSA and may be used in preparing effective antibiotic medicine. The structural expression of the quinolyl dione derivative is shown.

Description

Quinolyl dione derivative and the application in the preparation antibacterials thereof
Technical field
The present invention relates to a class quinolyl dione derivative and the purposes in the preparation antibacterials thereof.This medicine particularly has very strong restraining effect to methicillin-resistant gold staphylococcus (MRSA) to gram-positive microorganism.
Background technology
The anti-microbial type medicine is the medicine that an at present the most frequently used class is treated bacterial infection.For many years along with microbiotic in the popularizing and using of the whole world, and have serious unreasonable abuse condition, no matter be that multiple Resistant strain has all appearred in gram positive bacterium or negative bacteria.Wherein the resistance problem of gram-positive microorganism is particularly serious, methicillin resistant staphylococcus aureus (the methicillin-resistant Staphylococcus aureus that occurs in the world wide, MRSA) and staphylococcus epidermidis (methicillin-resistant Staphylococcus epidermdis, MRSE), penicillin-fast streptococcus pneumoniae (penicillin-resistant Streptococcus pneunoniae, PRSP) and the faecalis of vancomycin resistance (vancomycin-resistant Enterococci, VRE) etc., be the current clinical middle serious problems that exist.The infection that these drug-resistant bacterias are caused also lacks effective medicine at present.Press for no cross resistance of development and more effective new texture antimicrobial drug.At present, can resist the newtype drug of Resistant strain, among developing and developing as a series of medicines such as streptogramin, daptomycin and oxazolidine ketones.
Summary of the invention
The purpose of this invention is to provide the new quinolyl dione derivative of a class, and this compounds is in preparation medicament for resisting gram-positive bacteria, the application in the medicine of particularly anti-methicillin-resistant gold staphylococcus (MRSA).
Quinolyl dione derivative of the present invention is as shown in the formula shown in the I:
Figure C20061003648400031
Formula I
R among the formula I 1The group of representative is :-H or C 1-C 4Alkyl etc.;
R among the formula I 2The group of representative is :-OH or-NH 2Deng;
R among the formula I 3The group of representative is :-H or-CH 3Deng.
Quinolyl dione derivative of the present invention can obtain by chemical synthesis process.Common quinolyl dione derivative of the present invention can prepare by following reaction (formula II):
Figure C20061003648400041
Formula II
Show that by extracorporeal bacteria inhibitor test quinolyl dione derivative of the present invention is to gram-positive microorganism, particularly anti-methicillin-resistant gold staphylococcus (MRSA) has very strong restraining effect, and to non-pathogenic bacteria, very little as the intestinal bacteria restraining effect.Animal acute toxicity test shows that this compounds toxicity is very low, IC 50Greater than 2.2g/kg mouse body weight.Therefore quinolyl dione derivative of the present invention can be used for preparation treatment gram positive bacteria infection, the medicine that particularly anti-methicillin-resistant gold staphylococcus (MRSA) infects.
The present invention also provides a kind of medicine that bacterium (gram-positive microorganism) infects that is used for the treatment of, and particularly treats the medicine that methicillin-resistant gold staphylococcus (MRSA) waits infection; This medicine contains above-mentioned quinolyl dione derivative and pharmaceutically acceptable auxiliary.This medicine can be made the form of injection, tablet, pill, capsule, suspension agent or emulsion and use.Its route of administration can be oral, through skin, and vein or intramuscular injection.
Embodiment
The invention will be further described by the following examples.
Embodiment one: compound K LT-2's is synthetic
With 6 of 0.01mol, 7-two chloro-5,8-quinolyl dione and 0.02mol methyl aceto acetate join in the dehydrated alcohol of 20-80mL, under agitation add the pyridine of 0.01-0.08mol, back flow reaction 2-15 hour.After the cooling, promptly there is solid to separate out, filters.The gained solid matter obtains orange-yellow quinolyl dione derivative KLT-2 through column chromatography for separation.m.p.221-223℃。m.p.221-223℃。 1H?NMR?δ9.74(d,1H),8.98(d,1H),8.43(d,1H),8.21(d,1H),7.80(d,1H),7.65(t,1H),7.43(t,1H),4.38(q,2H),1.39(t,3H)。MS(m/z):321(M ++1)。
The structural formula of quinolyl dione derivative KLT-2 is as follows:
Figure C20061003648400042
Embodiment two: quinolyl dione derivative KLT-N1's is synthetic
With 6 of 0.01mol, 7-two chloro-5,8-quinolyl dione and 0.02mol methyl acetoacetate join in the dehydrated alcohol of 20-80mL, under agitation add the 3-aminopyridine of 0.01-0.08mol, back flow reaction 5-25 hour.After the cooling, promptly there is solid to separate out, filters.The gained solid matter obtains the quinolyl dione derivative KLT-N1 of purple through column chromatography for separation.m.p.>350℃。 1H?NMR?δ9.20(d,1H),8.95(d,1H),8.40(d,1H),7.76(d,1H),7.21(d,1H),6.90(t,1H),6.72(d,1H),3.39(s,3H),3.14(s,2H)。MS(m/z):321(M +)。
The structural formula of quinolyl dione derivative KLT-N1 is as follows:
Embodiment three: quinolyl dione derivative KLT-N2's is synthetic
With 6 of 0.01mol, 7-two chloro-5,8-quinolyl dione and 0.02mol methyl aceto acetate join in the dehydrated alcohol of 20-80mL, under agitation add the 3-aminopyridine of 0.01-0.08mol, back flow reaction 5-20 hour.After the cooling, promptly there is solid to separate out, filters.The gained solid matter obtains the quinolyl dione derivative KLT-N2 of purple through column chromatography for separation.m.p.>350℃。 1H?NMR?δ9.20(d,1H),8.96(d,1H),8.40(d,1H),7.76(d,1H),7.20(d,1H),6.72(t,1H),4.42(q,1H),3.14(s,2H),1.34(t,3H)。MS(m/z):335(M +)。
The structural formula of quinolyl dione derivative KLT-N2 is as follows:
Figure C20061003648400052
Embodiment four: quinolyl dione derivative KLT-01's is synthetic
With 6 of 0.01mol, 7-two chloro-5,8-quinolyl dione and 0.02mol methyl acetoacetate join in the dehydrated alcohol of 20-80mL, under agitation add the 3-pyridone of 0.01-0.08mol, back flow reaction 5-20 hour.After the cooling, promptly there is solid to separate out, filters.The gained solid matter obtains orange-yellow quinolyl dione derivative KLT-01 through column chromatography for separation.m.p.>350℃。 1H?NMR?δ9.36(d,1H),8.93(d,1H),8.53(d,1H),7.79(d,1H),7.21(d,1H),6.82(d,1H),4.00(s,3H)。MS(m/z):322(M +)。
The structural formula of quinolyl dione derivative KLT-01 is as follows:
Figure C20061003648400053
Embodiment five: quinolyl dione derivative KLT-02's is synthetic
With 6 of 0.01mol, 7-two chloro-5,8-quinolyl dione and 0.02mol methyl aceto acetate join in the dehydrated alcohol of 20-80mL, under agitation add the 3-pyridone of 0.01-0.08mol, back flow reaction 5-20 hour.After the cooling, promptly there is solid to separate out, filters.The gained solid matter obtains orange-yellow quinolyl dione derivative KLT-02 through column chromatography for separation.m.p.>350℃。 1H?NMR?δ9.39(d,1H),8.92(d,1H),8.54(d,1H),7.78(d,1H),7.21(d,1H),6.82(d,1H),4.49(q,2H),1.46(t,3H)。MS(m/z):336(M +)。
The structural formula of quinolyl dione derivative KLT-02 is as follows:
Embodiment six: the quinolyl dione derivative anti-microbial activity is measured
Use MIC (μ g/ml) value of agar dilution determination test compound.
1. the preparation of antibacterials stoste: original liquid concentration is for measuring more than 10 times of maximum concentration, and with the degerming of filtration method, packing is standby in a small amount after preparing.
2. the preparation of pastille agar: stoste is diluted to 10 gradient concentrations with half dilution method.Get 1ml respectively and add a series of marks of having carried out, internal diameter is in the flat board of 90mm.Get the MH agar 19ml of 50 degree of having sterilized again, add in the flat board mixing postcooling.
3. inoculation: with inoculator inoculation one by one on the pastille flat board of drawing good mark, each inoculum size is 1~2 a μ L (bacteria containing amount about 10 6CFU/mL).Inoculation does not at last contain the growth control plate of medicine, to check the existing state of test bacterium in the whole experiment.
4. hatch: after treating that inoculation point bacterium liquid is done, flat board is put 37 ℃ and is hatched 18-24h.
5. the result judges: bacterium colony grow fully the lowest concentration of drug that suppressed fully for this medicine to detecting the MIC of bacterium.Single colony growth can be ignored.
The quinolyl dione compound of finding test demonstrates significant inhibition activity to several gram-positive microorganisms.Wherein, quinolyl dione derivative KLT-2 has very strong inhibition activity to the golden staphylococci (MRSA) of methicillin-resistant, and is active higher 4 times than the vancomycin of positive control.
Quinolyl dione derivative anti-microbial activity measurement result
Figure C20061003648400062

Claims (6)

1. suc as formula the quinolyl dione derivative shown in the I:
Formula I
R among the formula I 1The group of representative is :-H or C 1-C 4Alkyl; R 2The group of representative is :-OH or-NH 2R 3The group of representative is :-H or-CH 3
2. the described quinolyl dione derivative of claim 1 is as the application of preparation antibacterials.
3. according to the described application of claim 2, it is characterized in that described antibacterials are medicines of resisting gram-positive bacteria.
4. according to the described application of claim 2, it is characterized in that described antibacterials are medicines of anti-methicillin-resistant gold staphylococcus.
5. one kind is used for the antimicrobial medicine, it is characterized in that this medicine contains described quinolyl dione derivative of claim 1 and pharmaceutically acceptable auxiliary.
6. according to the described medicine of claim 5, it is characterized in that this medicine is injection, tablet, pill, capsule, suspension agent or emulsion.
CNB2006100364840A 2006-07-14 2006-07-14 Quinolyl dione derivative and its application in preparing antibiotic medicine Expired - Fee Related CN100441580C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006100364840A CN100441580C (en) 2006-07-14 2006-07-14 Quinolyl dione derivative and its application in preparing antibiotic medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100364840A CN100441580C (en) 2006-07-14 2006-07-14 Quinolyl dione derivative and its application in preparing antibiotic medicine

Publications (2)

Publication Number Publication Date
CN1887884A CN1887884A (en) 2007-01-03
CN100441580C true CN100441580C (en) 2008-12-10

Family

ID=37577166

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100364840A Expired - Fee Related CN100441580C (en) 2006-07-14 2006-07-14 Quinolyl dione derivative and its application in preparing antibiotic medicine

Country Status (1)

Country Link
CN (1) CN100441580C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102093358B (en) * 2011-02-21 2012-09-05 中山大学 Brominated indolizinoquinoline dione derivative and application of brominated indolizinequinoline dione derivative in preparing antibiotic medicament
AU2016205137B2 (en) * 2015-01-08 2020-01-30 Linkun AN Furoquinolinediones as inhibitors of TDP2

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028304A1 (en) * 1996-12-20 1998-07-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Pro-drugs and counterparts of camptothecin, their application as medicines
CN1354746A (en) * 1999-05-04 2002-06-19 日进素材产业株式会社 6.7-disubstituted-5,8-quinolinedione derivatives as antifungal agent
US20040063754A1 (en) * 2000-11-20 2004-04-01 Hisashi Takahashi Dehalogeno compounds
CN1491944A (en) * 2003-09-19 2004-04-28 中国医学科学院医药生物技术研究所 5-amino-8-methoxy quinolone carboxylic acid derivatives and its preparation
US6762181B1 (en) * 1999-03-10 2004-07-13 Daiichi Pharmaceutical Co., Ltd. Aminomethylpyrrolidine derivatives having aromatic substituents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028304A1 (en) * 1996-12-20 1998-07-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Pro-drugs and counterparts of camptothecin, their application as medicines
US6762181B1 (en) * 1999-03-10 2004-07-13 Daiichi Pharmaceutical Co., Ltd. Aminomethylpyrrolidine derivatives having aromatic substituents
CN1354746A (en) * 1999-05-04 2002-06-19 日进素材产业株式会社 6.7-disubstituted-5,8-quinolinedione derivatives as antifungal agent
US20040063754A1 (en) * 2000-11-20 2004-04-01 Hisashi Takahashi Dehalogeno compounds
CN1491944A (en) * 2003-09-19 2004-04-28 中国医学科学院医药生物技术研究所 5-amino-8-methoxy quinolone carboxylic acid derivatives and its preparation

Also Published As

Publication number Publication date
CN1887884A (en) 2007-01-03

Similar Documents

Publication Publication Date Title
CN111096964A (en) Combined application of quercetin and antibacterial drug
CN110123806B (en) Application of epigallocatechin gallate in preparation of anti-streptococcus suis drugs
JP2711202B2 (en) Staphylococcal antibacterial agent
Zuo et al. Effects of metformin on Streptococcus suis LuxS/AI-2 quorum sensing system and biofilm formation
CN100441580C (en) Quinolyl dione derivative and its application in preparing antibiotic medicine
Desouky et al. Effect of Salvia egypticae and Foeniculum vulgara extracts on quorum sensing and biofilm formation of methicillin resistant/sensitive Staphylococcus aureus isolates
CN108093637A (en) Novel bicyclic fat lanthiopeptin, preparation and the purposes as antimicrobial
CN108420814A (en) A kind of NPS-2143 is used for the new application of antibacterial
JPH0820510A (en) Spice having antimicrobial activity and antimicrobial agent prepared by using the same
CN100519533C (en) 5-arylamino quinolyl-7,8-dione derivative and its application in preparing antibiotic medicine
CN108498784A (en) Application of the Radix pseudostellariae cyclic peptides B in preparing anti-candida albicans drug
WO2010107793A1 (en) Methicillin-resistant staphylococcus aureus active metabolites
CN103113390A (en) Sulbactam sodium compound and medical composition of sulbactam sodium compound and mezlocillin sodium
CN109496211B (en) Piperazine derivative for resisting candida albicans as well as preparation method and application thereof
CN109925503B (en) Traditional Chinese medicine injection for reversing drug resistance of staphylococcus aureus
Hodinka et al. Comparative in vitro activity of IY146032 (daptomycin), a new lipopeptide antimicrobial
WO2002022147A1 (en) Antibacterial combination comprising neem plant extract
CN108578400A (en) Application of the nevadensin in preparing anti-candida albicans drug
CN109432107A (en) The composition and its application in the drug for preparing bacterial infection disease of melbine and Doxycycline
WO2018010403A1 (en) Use of medicinal nanomaterial composition dg-5 applied to anti-drug resistant bacteria
CN100451002C (en) Derivatives of 2,6-dipyridylene cyclohexanone, and its application in preparing antibacterial medicine
CN103980251A (en) Orixine derivative and application of orixine derivative in preparation of medicine for resisting drug-fast bacteria
CN110156737A (en) The application of a kind of pyranone compounds and its resisting pseudomonas aeruginosa biomembrane
CN110237058B (en) Application of citral in inhibition of growth of multidrug-resistant enterobacter heumakii
CN115487202B (en) Application of fidaxomicin in preparation of medicines for resisting nocardia infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081210

Termination date: 20150714

EXPY Termination of patent right or utility model